摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

tetra-n-butylammonium hydrogen sulfate | 36892-20-3

中文名称
——
中文别名
——
英文名称
tetra-n-butylammonium hydrogen sulfate
英文别名
n-butylammonium hydrogen sulfate;n-butylammonium bisulfate;butylamine; sulfate (1:1);butylammonium bisulfate;n-butylammonium sulfate;Butylammonium hydrogen sulphate;butylazanium;hydrogen sulfate
tetra-n-butylammonium hydrogen sulfate化学式
CAS
36892-20-3
化学式
C4H11N*H2O4S
mdl
——
分子量
171.218
InChiKey
AJSHDAOMUKXVDC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.2
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    116
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    tetra-n-butylammonium hydrogen sulfate 作用下, 以 为溶剂, 生成 正丁胺
    参考文献:
    名称:
    WO2007/79944
    摘要:
    公开号:
  • 作为产物:
    描述:
    正丁胺二氧化硫氧气 作用下, 以97.8%的产率得到tetra-n-butylammonium hydrogen sulfate
    参考文献:
    名称:
    Onium Sulfates and Hydrogen Sulfates: Products of Reactions of Sulfur(IV) Oxide with Aqueous Solutions of Alkylamines and Aniline
    摘要:
    The reaction products formed in the SO2-L-H2O-O-2 systems (L is n-propylamine, n-butylamine, tert-butylamine, n-heptylamine, n-octylamine, aniline) were isolated and identified as "onium" salts [n-C3H7NH3](2)SO4, [n-C4H9NH3](2)SO4, [t-C4H9NH3](2)SO4, [n-C7H15NH3](3)SO4(HSO4), [n-C8H17NH3](3)SO4(HSO4), and [C6H5NH3](2)SO4. The products were characterized by elemental analysis, IR and Raman spectroscopy, mass spectrometry, and thermogravimetry.
    DOI:
    10.1134/s0036023618050157
  • 作为试剂:
    参考文献:
    名称:
    [EN] ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION
    [FR] INHIBITEURS D'ALDH-2 DANS LE TRAITEMENT D'UNE ACCOUTUMANCE
    摘要:
    揭示了具有Formula I结构的新型异黄酮衍生物,可用作ALDH-2抑制剂,用于治疗哺乳动物对成瘾药物的依赖,例如对多巴胺类药物如可卡因、吗啡、安非他命、尼古丁和酒精的依赖。
    公开号:
    WO2009094028A1
点击查看最新优质反应信息

文献信息

  • Leukotriene LTD.sub.4 and LTB.sub.4 antagonists
    申请人:G. D. Searle & Co.
    公开号:US04923891A1
    公开(公告)日:1990-05-08
    This invention encompasses compounds of Formula I ##STR1## and the pharmaceutically acceptable salts and geometrical and optical isomers thereof wherein: X, Y, and Z are each independently O or S with S optionally oxidized to S=O; Alk is straight or branched chain alkylene or hydroxyalkylene containing 1-6 carbon atoms; R.sub.1 is hydrogen or lower alkyl; n is 0 to 5; R.sub.2 is hydrogen, lower alkyl, cycloalkyl, --(CH.sub.2).sub.n --CO.sub.2 R.sub.1, phenyl, phenyl substituted with halo, lower alkyl or lower alkoxy; and Ar is 5,6,7,8-tetrahydro-1-naphthalenyl, phenyl, or phenyl substituted with lower alkyl, hydroxy, lower alkoxy, or lower alkanoyl. This invention is in the field of pharmaceutical agents which act as leukotriene D.sub.4 (LTD.sub.4) antagonists and includes embodiments which act as leukotriene B.sub.4 (LTD.sub.4) antagonists.
    这项发明涵盖了Formula I的化合物##STR1##及其药用可接受的盐和几何和光学异构体,其中:X、Y和Z分别独立地为O或S,其中S可氧化为S=O;Alk为含有1-6个碳原子的直链或支链烷基或羟基烷基;R.sub.1为氢或较低的烷基;n为0至5;R.sub.2为氢、较低的烷基、环烷基、--(CH.sub.2).sub.n --CO.sub.2 R.sub.1、苯基、苯基取代物与卤素、较低烷基或较低烷氧基;Ar为5,6,7,8-四氢-1-萘基、苯基或苯基取代物与较低烷基、羟基、较低烷氧基或较低烷酰基。这项发明涉及作为白三烯D.sub.4(LTD.sub.4)拮抗剂的药用剂,包括作为白三烯B.sub.4(LTD.sub.4)拮抗剂的实施形式。
  • Thiazole derivatives
    申请人:Hoffman-La Roche Inc.
    公开号:US06001855A1
    公开(公告)日:1999-12-14
    Compounds of formula I ##STR1## as well as pharmaceutically usable salts and esters thereof, wherein R.sup.1, R.sup.2 and R.sup.3 have the significance given in claim 1, inhibit the binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. They can be used in the form of pharmaceutical preparations in the control or prevention of neoplasms, tumor metastasing, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, kidney failure as well as infections caused by viruses, bacteria or fungi.
    式I的化合物##STR1##以及其药用盐和酯,其中R.sup.1,R.sup.2和R.sup.3具有权利要求1所述的含义,可以抑制黏附蛋白质与不同类型细胞表面的结合,从而影响细胞-细胞和细胞-基质相互作用。它们可以以药物制剂的形式用于控制或预防肿瘤,肿瘤转移,骨质疏松症,Paget病,糖尿病视网膜病变,黄斑变性,血管介入后再狭窄,牛皮癣,关节炎,肾衰竭以及由病毒,细菌或真菌引起的感染。
  • Talukdar,P.B., Journal of the Indian Chemical Society, 1967, vol. 44, p. 17 - 22
    作者:Talukdar,P.B.
    DOI:——
    日期:——
  • Wang, Zhi Yuan; Just, George, Synthetic Communications, 1988, vol. 18, # 5, p. 469 - 472
    作者:Wang, Zhi Yuan、Just, George
    DOI:——
    日期:——
  • VON KIYOSHI KONDO; SATOSHI YOKOYAMA; NORITAKA MIYOSHI; SHINJI MURAI; NOBO+, ANGEW. CHEM., 1979, 91 NO 9, 760-761
    作者:VON KIYOSHI KONDO、 SATOSHI YOKOYAMA、 NORITAKA MIYOSHI、 SHINJI MURAI、 NOBO+
    DOI:——
    日期:——
查看更多